Ceapro had a webcast today hosted by HCWCo, this is available on CZO's website; some notes;
HCWCo Sept 16 Webcast notes
1)AV pill
Develop AV as pharmaceutical for anti-inflammatory, have pharma grade formulation, initiate phase 1 by end of year
2) Y-BG for Covid
Inhalable treatment for existing oral dosage drug for pulmonary fibrosis, found Y-BG purified worked alone as anti-inflammatory, good to see this was mentioned as some investors would definitely be interested in the Covid angle
3) PGX plant
Last week equipment found in Germany, will install in Germany to manufacture PGX Y-BG alone (“masterpiece of CZO strategy”) , but impregnate with bioactives as needed in Edmonton (impregnation equipment coming from US), all ready by mid 2021 (I believe this is still in-line with Noble analyst which reported : We assume the scale up of Ceapro's manufacturing and processing plant implementing novel applications of PGX technology and related technologies will be completed in F2022, which will positively impact future revenue growth.
4) Financials
Also good to see the positive H1 financials were mentioned, though no EPS given, perhaps not that important from the company perspective but maybe for some investors
5) PGX deal
Deal for a chemical complex still on track for H2 2020
6) NASDAQ uplisting
Hired advisor for uplisting
As for the PGX chicken and egg question, seems like if you have a plan for the plant, it’ll be easier to get a deal signed, we are that much closer to a PGX deal. It appears they would get upfront milestone payments on a signed deal but rev from commerical product may be not be unitl mid 2021 (unless of course small trial production volumes at current plant). |
